Reproductive Health Marketing Consultant & Advisor
Fertility Clinic, IVF, Donor Program, Reproductive Health, Surrogacy & Family-Building Growth Strategy.
I help fertility clinics, IVF practices, surrogacy agencies, donor programs, cryostorage companies, sexual-health practices and other reproductive-health organizations grow through strategy, SEO, GEO, AI search, paid media, reputation and better patient or client journeys.
Reproductive health can involve an endocrinologist, embryology lab, donor bank, urologist, attorney, genetic counselor, mental-health professional, employer benefit, travel plan and a cryogenic tank before anybody gets to the part people casually call “starting a family.” The work is making that complicated system easier to understand, find, trust and navigate.
Marketing and growth strategy only. Clinical, legal, genetic, privacy and reproductive-law decisions stay with appropriately qualified professionals.
Reproductive health is where medicine, identity, biology, time, money and hope all show up to the same appointment.
That is precisely why generic healthcare marketing performs so poorly here.
I start with the actual business and care system. Then I connect positioning, search, AI discovery, websites, content, reputation, paid media, referrals and measurement to the parts that need to change.
From the first private search to treatment, storage, follow-up and long-term trust.
Fertility is one market inside a much larger reproductive-health economy.
I work across the businesses and care systems that sit around fertility and reproductive health: IVF and reproductive endocrinology, donor programs, gestational carriers, cryostorage, reproductive genetics, male fertility, sexual medicine, benefits, laboratories, advocacy, patient education and the handoffs connecting them.
For fertility clinics, IVF centers and reproductive endocrinology practices, I also work specifically on fertility clinic marketing and growth strategy. That work is personal to me, and I explain why there. Here, I am looking at the larger reproductive-health market and the organizations that have to coordinate around the person receiving care.
A person can enter this world through infertility, cancer treatment, egg freezing, recurrent pregnancy loss, male-factor evaluation, donor conception, sexual pain, erectile dysfunction, menopause, contraception, a genetic concern or the desire to build a family through a less conventional path. Some infrastructure overlaps. The emotions, economics, regulations and decisions can be very different.
The reproductive-health market includes far more than the clinic performing the procedure.
A reproductive-health strategy can serve organizations with completely different buyers, revenue models, compliance obligations and definitions of a successful outcome.
Fertility & REI
Fertility clinics, IVF centers, reproductive endocrinologists, multi-location groups, preservation programs and specialist physician practices.
Donor & Carrier Programs
Sperm banks, egg donor programs, embryo donation, gestational-carrier programs, surrogacy agencies and intended-parent services.
Labs, Genetics & Cryostorage
Embryology, reproductive genetics, PGT-related services, andrology, cryobanks, storage operations and laboratory partners.
Sexual & Reproductive Care
Sexual medicine, reproductive urology, pelvic health, contraception, menopause care and services that overlap fertility without being defined by it.
Benefits, Finance & Navigation
Employer fertility benefits, navigation companies, financing, patient access programs and organizations helping people understand cost and coverage.
Education, Advocacy & Support
Nonprofits, patient communities, counseling resources, professional organizations and mission-driven groups working to reduce confusion and stigma.
The commercial question changes with the organization. A fertility clinic needs qualified consultations and treatment starts. A donor bank may need donors and recipients. A surrogacy agency may need intended parents and qualified carrier applicants. A benefits company may be selling to an employer while serving a member who never chose the vendor. The marketing should understand the business before it starts buying attention.
A beautiful fertility website cannot fix a clinic that has the wrong demand, no capacity or a broken consultation handoff.
Before spending money on SEO, PPC or a redesign, I want to understand what the organization is trying to grow. More IVF starts? More fertility-preservation consults? Better-fit donor cases? A new physician? A new location? A male-fertility service line? A stronger referral base? A cryostorage business? An employer-benefit contract?
Fertility care has unusually long consideration cycles and unusually emotional economics. A lead can represent months of research, repeated website visits, conversations with a partner, financing decisions, lab work, prior treatment failures and quiet second opinions. The organization that treats that journey like an ordinary lead form will misread both the patient and the data.
Demand
What care is the market actually seeking, and how urgent is the decision?
Fit
Which patients and cases match the physicians, laboratory, service lines and capacity?
Conversion
What happens after the inquiry, from first call through consultation and treatment start?
Economics
Which mix of services, payer models, storage, laboratory work and referrals makes growth sustainable?
Fertility is large enough to be a serious market and sensitive enough that the numbers need humility.
CDC says roughly 500 U.S. clinics provide assisted reproductive technology services, and its National ART Surveillance System contains an estimated 98 percent of ART cycles. Clinics performing ART report data annually under the Fertility Clinic Success Rate and Certification Act. Public outcome data are therefore part of the buying environment in a way that is unusual for many healthcare markets.
The sector is also substantial. In March 2026, ASRM reported that SART-member clinics recorded 449,772 IVF treatment cycles in 2024, with 100,158 babies born through IVF. It was the first time the annual number reported by SART exceeded 100,000 births.
Those numbers still need context. CDC warns that clinic comparisons can mislead because age, diagnosis, ovarian reserve, treatment methods, patient selection and cycle volume can differ. Published data also lag current practice because treatment, birth follow-up, reporting, validation and publication take time.
The patient can arrive carrying a spreadsheet, grief, hope and three browser tabs open at 1:17 a.m.
Fertility care creates a peculiar combination of clinical complexity and repeated decision-making. People may compare physicians, protocols, laboratory capability, timing, donor options, success data, finances, geography, reviews and bedside manner while also trying to function at work and explain the process to family members who may not understand any of it.
A strong digital experience should reduce cognitive load. It should explain enough science to support an informed conversation without pretending to replace the physician. It should also make the next step obvious without turning hope into a sales device.
The website has one job before the first appointment
Make the patient less confused than when they arrived. If a person leaves with seventeen new acronyms and no idea what happens next, the content was technically informative and practically useless.
The hardest question on the page may be the one somebody is embarrassed to ask at all.
Infertility, pregnancy loss, failed treatment, donor conception and questions about sexual health can carry grief, shame, isolation, anger, relationship strain and the exhausting feeling that everybody else seems to know how your life should work.
Communication can either lighten that load or make it worse. I do not want fertility copy that blames the patient, treats male-factor infertility like an awkward footnote, turns miscarriage into a motivational slogan, or makes somebody feel defective because the path to parenthood looks different from the one they expected.
Support belongs in the pathway
Organizations can make counseling, support groups, grief resources, financial navigation, peer education and referral options easier to find. The point is not to turn a marketing department into a therapy practice. The point is to stop hiding the help people may need.
ASRM's 2026 recurrent-pregnancy-loss guidance says psychological support is an essential part of miscarriage care and should be offered to couples experiencing miscarriage and planning a future pregnancy. That is clinical guidance, not a marketing slogan. For the business and communication side, it means emotional support should be visible, accurate and easy to reach.
When counseling or relationship care is part of the service ecosystem, I also have a live Mental Health Counselor Consultant & Advisor resource for the business and communication side of that work.
IVF is a treatment pathway, a laboratory workflow, a financial commitment and an emotional marathon at the same time.
IVF sits at the center of many fertility journeys, but the business system extends far beyond the physician visit. It connects reproductive endocrinologists, embryology labs, pharmacies, monitoring, retrieval, fertilization, embryo culture, transfer, storage, genetics, billing, travel and follow-up.
Marketing has to make those relationships understandable. Physician reputation may earn the first click. Laboratory capability, nursing, access, financial counseling, communication and the quality of the handoff often shape the experience that follows.
If you operate an IVF clinic or reproductive endocrinology practice, see my Fertility Clinic Marketing Consultant & Advisor work for the clinic-specific growth, patient-acquisition, SEO, GEO, PPC and operational side.
Clinical authority
REI expertise, difficult cases, second opinions, treatment philosophy and care coordination.
Laboratory trust
Embryology, quality systems, chain of custody, cryostorage, genetic workflows and clear explanations.
Patient experience
Scheduling, medication teaching, portal communication, financial navigation and the many small moments that become the memory of care.
Egg freezing is not infertility marketing with the calendar moved earlier.
Fertility preservation can be elective, medically indicated or connected to cancer and other treatments that may affect future fertility. The decision is often about keeping options open, which means communication should be careful about uncertainty. Preservation is possibility, not a guarantee.
The patient journey may include ovarian reserve education, consultation timing, medication, retrieval, storage fees, future use and questions about how long material can remain stored. Oncology-related preservation adds urgency and requires coordination across specialties.
Half the reproductive equation should not be hiding in a footer.
Male fertility can involve semen analysis, azoospermia, oligospermia, varicocele, endocrine evaluation, genetics, surgical sperm retrieval, fertility preservation and coordinated care with IVF. The buyer journey can also be different. Some men enter through a urologist. Some arrive after months of fertility treatment focused elsewhere. Some search privately before discussing the concern with anybody.
That makes direct, nonjudgmental language important. Search pages should explain what type of specialist evaluates the concern, what a first appointment may involve and how male-factor care connects to the larger family-building plan.
Third-party reproduction creates relationships that can last much longer than the treatment cycle.
Donor programs operate at the intersection of clinical care, screening, genetics, psychology, consent, records, privacy and long-term family questions. ASRM's 2024 gamete and embryo donation guidance emphasizes donor screening and testing, genetic evaluation, psychoeducational counseling and the reality that direct-to-consumer DNA testing has changed expectations around anonymity.
That last point matters commercially too. A donor program cannot market anonymity as if technology stopped in 1998. Public copy should explain the program's actual identity-release practices, records, counseling and future-contact framework with precision.
The intake form should not assume the family before the clinic meets the family.
Reproductive medicine may serve married heterosexual couples, same-sex couples, LGBTQ+ family-building patients, single intended parents, people using donor gametes, families using donated embryos and intended parents working with gestational carriers. The clinical pathway can change substantially depending on whose eggs, sperm and uterus are involved.
That makes inclusive language a practical accuracy issue. A page about donor sperm should not force every visitor into a husband-and-wife narrative. A gestational-carrier page should identify the medical and legal participants clearly. A clinic can communicate who it serves without turning every sentence into a demographic inventory.
The best approach is usually simple: describe the real pathways, use respectful language, explain the expertise, and let people recognize themselves in accurate information.
The word donor has a regulatory meaning before it becomes a marketing persona.
FDA regulates reproductive cells and tissues under the HCT/P framework. Donor eligibility, screening and testing requirements depend on the type of tissue and the relationship between donor and recipient. FDA guidance also distinguishes sexually intimate partners, directed donors, anonymous donors and gestational carriers.
That complexity belongs in operations and compliance. Marketing's job is simpler: do not invent regulatory shortcuts. Explain what the program actually does, use the correct terms, and send legal or clinical questions to the people responsible for them.
There are more stakeholders in the room, and every one of them is a person.
“Surrogacy” is the common search language. In many clinical settings, gestational carrier is the more precise term because the person carrying the pregnancy is not genetically related to the child. Public communication should understand both the language people use and the language the clinical, agency and legal teams need.
A gestational-carrier journey can involve intended parents, the carrier, fertility clinic, donor programs, attorneys, mental-health professionals, agencies, escrow or financial services, insurers, obstetric care and sometimes international travel. Every handoff can create uncertainty, and every organization involved has a different duty to communicate accurately.
There are two human journeys here
Intended parents may be searching for a path after infertility, medical risk, repeated treatment, family structure or another personal reason. A prospective carrier is making a different medical, emotional and family decision. The same cheerful campaign should not be used to talk to both.
ASRM's ethics guidance emphasizes carrier autonomy, informed consent, psychological evaluation and independent legal counsel. State law varies, and international arrangements add another legal system. I can help with positioning, education, search, intake, reputation and market strategy. Legal conclusions belong with qualified reproductive-law counsel.
The tank is invisible to the patient until suddenly it represents years of decisions.
Cryostorage can involve sperm, oocytes, embryos and other reproductive material. The business questions include storage fees, renewals, contact information, custody, transfer requests, chain of custody, consent, disposition instructions, disaster planning and what happens if ownership or business relationships change.
This is an area where reassuring copy can become dangerous if it outruns the actual process. The website should explain what the organization can responsibly explain, publish clear contact pathways and avoid promises about permanence or risk that belong in validated operational documents.
Genetic information can improve decisions. It does not abolish uncertainty.
Carrier screening, preimplantation genetic testing, family history and genetic counseling are powerful parts of reproductive medicine. They are also easy to oversimplify. A marketing page should distinguish screening from diagnosis, explain limitations, clarify which professional interprets results and avoid implying that a result guarantees a future outcome.
For organizations that also operate laboratories or diagnostic businesses, the related Laboratory Marketing resource provides a deeper B2B and diagnostic-market bridge.
A patient rarely searches for the category name printed on the clinic org chart.
People arrive through specific concerns: PCOS, endometriosis, diminished ovarian reserve, recurrent pregnancy loss, tubal factor, ovulatory disorders, uterine factors, male factor, unexplained infertility, genetic risk or the need for fertility preservation. Each concern creates a different information need.
Search strategy should make those pathways explicit without creating a thin page for every diagnosis. A strong page explains what the concern means, who evaluates it, how it connects to fertility and what the next clinical conversation usually tries to clarify.
Diagnosis intent
The person already knows the condition and wants the right specialist or next step.
Symptom intent
The person knows something is wrong but may not know the reproductive-health term.
Second-opinion intent
The person has a diagnosis or prior treatment and is evaluating a different path, physician or clinic.
Sexual health deserves its own dignity. It should not be treated as a side effect of fertility.
Sexual medicine can include erectile dysfunction, sexual pain, pelvic health, libido concerns, ejaculatory dysfunction, menopause-related symptoms, vulvovaginal concerns, STI services, contraception, medication effects and relationship or mental-health factors. Some problems overlap fertility. Many do not.
The digital challenge is trust. Patients may search privately, use euphemisms, ask full-sentence questions and delay care because they are embarrassed. Clinical pages should be direct enough to answer the question and human enough to reduce shame.
Mental and relational support may be part of some journeys. The live Mental Health Counselor Consultant & Advisor resource is a natural adjacent authority when emotional or relationship care is part of the service ecosystem.
The same person can have completely different reproductive-health priorities at 22, 32, 42 and 52.
Reproductive health is not one age bracket. The questions change across contraception, fertility planning, pregnancy attempts, infertility, preservation, postpartum transitions, sexual function, perimenopause and menopause. Organizations that serve several stages should make those transitions understandable rather than building a website that feels like unrelated departments sharing a logo.
Good lifecycle design helps the right person find the right entry point without implying that every visitor wants pregnancy or that every reproductive-health concern belongs in a fertility clinic.
The person receiving care may not be the person buying the benefit.
Employer fertility-benefit and navigation companies operate in a two-sided market. Employers and benefits leaders evaluate cost, access, network quality, member experience, administration and outcomes. Members evaluate if the benefit actually helps them find care, understand coverage and move through a deeply personal process with less friction.
That means B2B demand generation, sales enablement and member communication need different messages. A benefits deck can be economically rigorous. A member page should feel like help, not procurement software.
Hope does not make the invoice smaller.
Fertility treatment can combine consultations, diagnostics, medications, procedures, laboratory work, anesthesia, genetics, donor costs, agency costs, legal costs, travel, storage and repeat cycles. Insurance coverage varies by plan and geography. Self-pay and financing are common enough that financial communication becomes part of conversion and trust.
I want patients to understand the economic structure early enough to make a responsible decision. That does not mean turning the homepage into a price sheet. It means clear paths to benefits verification, estimates, medication information, financing, storage fees and what is included in a quoted package.
Fertility can turn geography into part of the treatment protocol.
Patients travel for physician expertise, donor availability, treatment timing, legal environment, pricing, family-building pathways, privacy or because the local market does not offer the service they need. Travel can add remote consultations, monitoring coordination, medication logistics, hotel stays, time away from work and handoffs to local clinicians.
A destination fertility program should explain that operating system. Search visibility alone is insufficient if the patient cannot understand how treatment works from another state or country.
Reproductive privacy copy needs a calendar and a lawyer nearby.
Privacy has been legally dynamic. HHS states that a federal court vacated most of the 2024 HIPAA Privacy Rule to Support Reproductive Health Care Privacy on June 18, 2025. Certain Notice of Privacy Practices modifications remained, and their compliance date was February 16, 2026. That means old summaries of the 2024 rule can now be wrong.
I would keep public language grounded in actual organizational practices: what information is collected, how contact forms work, who receives inquiries, what patient portals are used and which privacy statements have been reviewed by the appropriate compliance team.
A review can help somebody feel less alone. It can also reveal more than a patient meant to publish.
Fertility and sexual-health reputation strategy needs restraint. Clinics can encourage feedback without pressuring people to discuss diagnoses, pregnancy status, donor use or sexual concerns publicly. Responses should avoid confirming a treatment relationship or arguing about clinical details in public.
Reputation is bigger than star ratings anyway. Physician bios, staff communication, scheduling, financial clarity, search results, third-party profiles and the quality of educational content all contribute to trust. The broader Reputation Management Consultant & Advisor page covers that discipline in more depth.
The website should feel clinically serious without feeling like a laboratory refrigerator.
Reproductive-health sites often swing between two extremes: emotionally overproduced lifestyle imagery and dense clinical information that assumes the visitor already speaks fluent embryology. The better approach combines warmth, direct answers, physician authority, process clarity and enough scientific depth to earn trust.
High-value pages should answer who the service is for, who provides it, what the process involves, what important limits exist, what a consultation can clarify and how to take the next step. The call to action should feel like access to a conversation, not pressure to buy a cycle.
People ask fertility questions long before they search a clinic name.
Traditional SEO still matters. Local Maps, treatment pages, physician entities, technical health, internal links, reviews and geographic relevance all influence discovery. AI assistants and answer engines add another layer because people increasingly ask complete questions and expect a synthesized response.
That creates an opportunity for strong first-party information. A clinic should make its physicians, services, locations, conditions treated, donor programs, preservation options, laboratory relationships and consultation process easy for search systems to distinguish.
For deeper search-system strategy, see AI Search & Organic Growth.
Voice-style questions
Who treats recurrent pregnancy loss near me? What kind of doctor evaluates male infertility? Where can I freeze eggs? What should I ask before choosing an IVF clinic?
Entity clarity
Clinic, physician, specialty, location, service, condition, laboratory, donor program and patient pathway should be explicit enough that a search system does not have to guess.
The most expensive click on the page is the one that lands on the wrong promise.
IVF, egg freezing, donor programs and specialty fertility searches can carry high commercial value. PPC needs intent segmentation, geographic discipline, negative keywords, strong landing pages, call tracking and enough clinical context to reduce poor-fit inquiries.
Paid media also has to match capacity. If the earliest new-patient consultation is eight weeks away, buying another thousand clicks may produce frustration faster than growth. Marketing volume and operating access belong in the same conversation.
A family-building story is a human story before it is content.
Social can help clinicians teach, normalize questions, explain treatment and create familiarity. It can also become invasive very quickly. Patient stories require permission and judgment. Before-and-after logic does not translate cleanly to fertility, and emotional outcomes should never be packaged like guaranteed product results.
The strongest content often comes from physician explanation, embryology education, practical expectations, myth correction, staff expertise and thoughtful answers to questions patients are already afraid to ask.
AI can organize information. It should not impersonate the reproductive endocrinologist.
AI can support research, content operations, analytics, call categorization, FAQ discovery, translation assistance and repetitive administrative tasks. In a sensitive reproductive-health environment, the boundaries matter just as much as the efficiency.
Clinical interpretation, genetic counseling, informed consent, diagnosis, treatment recommendations and emotionally consequential conversations need appropriate human responsibility. Patient data also require privacy, security and governance beyond a marketing team's enthusiasm for a new tool.
A fertility practice can have a marketing problem. It can also have a retrieval schedule wearing a marketing-problem costume.
Demand has to fit physician time, nursing, ultrasound, operating rooms, embryology, anesthesia, lab capacity, medication teaching, financial counselors and storage operations. A campaign that overwhelms one bottleneck can make the experience worse even while the lead dashboard looks wonderful.
That is why I care about access metrics: time to consultation, unanswered calls, abandoned forms, time to financial counseling, no-show rate, treatment-start rate and the handoffs between departments. Marketing should reveal operational friction, not hide it.
The laboratory may be invisible to the patient. It is not invisible to the outcome or the trust decision.
Fertility programs are unusual because some of the most consequential work happens after the patient leaves the room.
Embryology creates a communication challenge. The science is technical, the work is high stakes, and many patients have only a vague picture of what happens between retrieval and transfer. A strong program can explain laboratory leadership, quality systems, embryo culture, cryopreservation, identification, chain of custody and the role of genetic testing without turning the site into a textbook.
Operationally, the laboratory can also become a growth constraint. Physician demand, retrieval volume, incubator capacity, staffing, cryostorage, weekend coverage, quality control and communication all have to move together. A marketing plan that grows retrieval volume without understanding the laboratory is simply moving the bottleneck into a room the dashboard does not show.
Not every fertility patient starts with Google.
OB-GYNs, primary-care physicians, oncologists, urologists, genetic counselors, therapists, employers, benefits navigators and prior fertility patients can all influence referral flow. That means growth should not depend entirely on direct-to-consumer search.
A referral strategy should make it easy for another professional to understand which cases fit the practice, which physicians own which expertise, how quickly a patient can be seen, what records are needed and what happens after the referral. For oncology fertility preservation, speed and coordination matter even more because treatment timing can compress the decision window.
Clinical referrals
Clear indications, physician relationships, access and reliable communication back to the referring clinician.
Professional partnerships
Genetics, counseling, urology, surgery, maternity care, legal professionals and other partners who support the larger pathway.
Patient advocacy
Education and reputation strong enough that a former patient can describe the experience without needing to become a salesperson.
The first fertility consultation starts before the reproductive endocrinologist enters the room.
Someone has to answer the call, reply to the form, explain the first appointment, collect records, discuss insurance, schedule testing and reduce the fear that the patient is already behind. Those interactions can determine if a strong clinical program ever gets the chance to demonstrate its quality.
I pay close attention to response time, phone routing, voicemail, form length, scheduling options, financial handoffs and the language used by the first person who responds. A patient who has spent two years trying to get pregnant does not need to spend another week wondering if the clinic received the form.
Automation can help with confirmations, document requests and routine instructions. It should not make intimate care feel like a luggage-tracking system. The technology should remove repetitive friction so people have more time for the conversations that need judgment and empathy.
Growth depends on more than adding another physician bio.
Fertility organizations rely on reproductive endocrinologists, nurses, medical assistants, sonographers, embryologists, andrologists, laboratory leaders, genetic counselors, financial teams, schedulers and patient coordinators. Some roles are difficult to recruit and even harder to replace quickly.
That means workforce strategy affects marketing capacity. A new location cannot operate on brand awareness alone. A donor program cannot scale without the people who screen, counsel, coordinate and document it. A call center cannot repair an access problem if every consult slot is already full.
Employer reputation matters too. People working in high-emotion healthcare absorb the consequences of poor communication and unrealistic volume. Retention, training, role clarity and healthy workload are part of the patient experience long before they become a recruiting campaign.
Reproductive healthcare can cross a state line faster than the legal assumptions do.
Surrogacy, parentage, insurance, privacy, reproductive services and professional rules can vary by jurisdiction.
I do not turn a marketing page into legal advice. I do want the organization to know where its public language depends on a legal conclusion. Gestational-carrier programs are an obvious example. Contracting, parentage, compensation, independent counsel and permissible arrangements can vary. International family-building adds another legal system entirely.
The same discipline applies to privacy and sensitive services. If a rule has changed, the page should change. If a state-specific claim needs counsel, get counsel. If a program serves patients across multiple states, generic compliance language may be less reassuring than a clear explanation of where the clinical and legal handoffs occur.
The best fertility content answers the question people are afraid to ask badly.
Reproductive-health content should be medically literate and emotionally readable. That can include physician explanations, treatment comparisons, process guides, cost questions, fertility-preservation timelines, donor-conception education, male-factor information, reproductive genetics, sexual-health concerns and what a first visit actually looks like.
The goal is not a publishing quota. I would rather have ten genuinely useful pages than fifty articles that rearrange the phrase “IVF success.” Strong content supports organic search, AI retrieval, referral education and consultation quality at the same time.
It can also reveal personality. A physician can be serious without sounding sterile. An embryologist can explain the laboratory without turning the reader into an embryologist. A practice can show warmth without promising hope as if it were a clinical endpoint.
You do not need to diagnose the marketing problem before calling me.
Tell me what is happening. Maybe consultation volume is down. Maybe it is up and treatment starts are flat. Maybe a new physician needs visibility. Maybe the practice is expanding. Maybe the donor program is difficult to explain. Maybe the site ranks and still does not feel trustworthy. Maybe the problem is upstream from marketing entirely.
I can work as an advisor, strategist or hands-on partner across positioning, SEO, GEO, AEO, AI Search Optimization, PPC, content, websites, reputation, analytics, referral development and growth planning. I like complicated markets because the answer usually appears after the pieces are connected.
And if the right answer is “do not spend money on that yet,” I am perfectly comfortable saying it.
The useful conversion is not always the form submission.
For a fertility clinic, the path might be search to consultation request to attended consult to diagnostic workup to treatment plan to cycle start. For a donor program, it may be application to screening to acceptance to match. For a benefits company, it may be employer lead to procurement cycle to contract to member activation.
Those journeys require different dashboards. I would rather track the point where value is created than celebrate a large pile of low-context leads.
Reproductive care can be local, regional, national and international on the same Tuesday.
Local search matters for monitoring, consultations, sexual-health services and routine access. Regional and national visibility can matter for complex fertility cases, donor programs, preservation, unique physician expertise and second opinions. International demand can introduce travel, records, language, legal and payment questions.
Florida is useful context because it is home, not because every reproductive-health paragraph needs a Florida city inserted into it. The market should determine the geography.
Reproductive-health copy needs current sources because the law, data and clinical guidance can change.
CDC ART surveillance
CDC reports clinic-level ART data, standardized success rates and national surveillance through NASS. Public outcome data should be interpreted in context.
FDA reproductive tissue
FDA HCT/P rules and guidance govern donor eligibility, screening, testing and labeling in reproductive cells and tissues.
ASRM professional guidance
ASRM guidance adds clinical, ethical, genetic, psychological and legal considerations around gamete donation and gestational carriers.
HHS privacy status
The federal reproductive-health privacy rule changed after a 2025 court decision, so public compliance summaries need current review.
Sources used for current claims include CDC NASS, CDC ART success-rate interpretation, ASRM 2026 IVF activity report, ASRM recurrent-pregnancy-loss guidance, ASRM donation guidance, ASRM gestational-carrier ethics guidance, and HHS reproductive-health privacy guidance.
Questions fertility, reproductive-health and sexual-health organizations tend to expose.
What does a fertility and reproductive health marketing consultant do?
I help fertility clinics, IVF programs, reproductive endocrinologists, surrogacy and donor programs, cryostorage businesses, sexual health practices and related organizations improve positioning, patient education, search visibility, AI discovery, websites, reputation, referral strategy, conversion and sustainable growth.
Do you work specifically with fertility clinics and IVF practices?
Yes. I work specifically with fertility clinics, IVF centers and reproductive endocrinology practices on positioning, patient acquisition, treatment growth, SEO, GEO, PPC, reputation, consultation conversion and the operating friction that can limit growth. I also maintain a dedicated fertility-clinic strategy resource for that work.
What kinds of reproductive-health organizations can you help?
The work can support fertility and IVF programs, reproductive endocrinology groups, donor and surrogacy organizations, cryostorage businesses, reproductive genetics and laboratory services, male fertility and sexual-medicine practices, employer fertility-benefit companies, patient-navigation programs, nonprofits and other organizations serving reproductive health.
Should fertility clinics advertise success rates?
Success data require careful context. CDC cautions that comparisons between clinics may be misleading because patient populations and treatment methods differ. A clinic should present required and appropriate outcome information accurately, explain the denominator and timeframe, and avoid turning population statistics into an implied promise for one patient.
How does CDC regulate fertility clinic success-rate reporting?
The Fertility Clinic Success Rate and Certification Act requires clinics performing assisted reproductive technology to report ART data annually to CDC. CDC publishes clinic-specific success rates and says the National ART Surveillance System contains an estimated 98 percent of ART cycles in the United States.
Can you help fertility preservation and egg-freezing programs?
Yes. Fertility preservation has a different decision journey from infertility treatment. Messaging may need to address age, timing, future family goals, cancer treatment, career or life planning, storage, costs, uncertainty and what the process can and cannot guarantee.
Can you help sperm banks, egg donor programs and embryo donation programs?
Yes. These businesses need strong trust, clear donor and recipient education, careful claims, privacy, screening and testing communication, chain-of-custody clarity, genetics information and a digital experience that respects the long-term human implications of donor conception.
Do FDA donor rules apply to reproductive cells and tissues?
Yes. FDA regulates reproductive cells and tissues under the HCT/P framework. Donor eligibility requirements vary by the relationship between donor and recipient and by the type of donation. Clinical and legal teams should own compliance decisions while marketing communicates the process accurately.
Can you help gestational carrier and surrogacy programs?
Yes. Strategy can address intended-parent education, carrier recruitment or communication where appropriate, clinic and agency relationships, legal handoffs, psychological support, geographic markets, international patients, trust and the long decision cycle. State law varies, so legal claims should be reviewed by qualified counsel.
Is a gestational carrier considered a reproductive tissue donor under FDA rules?
FDA guidance states that a gestational or surrogate carrier is considered an HCT/P recipient rather than a donor. Separate donor-eligibility questions may apply to the sperm and oocyte sources used to create an embryo.
Can you help male fertility and andrology practices?
Yes. Male fertility can include semen analysis, azoospermia, oligospermia, reproductive urology, surgical sperm retrieval, varicocele, hormonal evaluation, genetics, fertility preservation and coordinated care with IVF programs. Search and referral patterns differ from female-focused fertility journeys.
Does sexual health belong on the same page as fertility?
It belongs in the same broad reproductive-health ecosystem, but it should remain a distinct care journey. Sexual medicine may involve erectile function, sexual pain, libido concerns, pelvic health, STI services, contraception, menopause-related concerns and relationship or mental-health factors. The message should protect privacy and avoid reducing every concern to fertility.
Can you help sexual medicine and sexual health practices with SEO?
Yes. Search strategy can clarify clinical scope, credentials, privacy, conditions treated, appointment options, local availability and the difference between medical sexual-health services and nonclinical wellness claims. Natural-language questions are especially important in this category.
How should reproductive health organizations approach privacy marketing in 2026?
Privacy claims need current legal review. In June 2025 a federal court vacated most of the 2024 HIPAA reproductive-health privacy rule, while certain Notice of Privacy Practices changes remained in effect. Their compliance date was February 16, 2026. Marketing should describe actual privacy practices and avoid repeating stale summaries of a rule that changed in court.
Can you help reproductive genetics and PGT programs?
Yes. Reproductive genetics needs precise language around screening, testing, risk, limitations and counseling. Marketing should explain what a test informs without implying certainty that the test cannot provide.
Can you help fertility clinics attract patients from other states or countries?
Yes. Some fertility patients travel for physician expertise, donor options, timing, pricing, legal environment, family-building pathways or treatment availability. Strategy may involve destination search, international patient services, travel logistics, records, remote consultations and continuity with home clinicians.
What role do reviews play in fertility marketing?
Reviews can reduce uncertainty, but this is a sensitive category. A clinic should never pressure patients to disclose intimate medical details. Reputation strategy should focus on experience, communication, access, professionalism and truthful public information while respecting privacy.
Can you help with fertility clinic PPC and paid search?
Yes. Paid search can be useful for IVF, egg freezing, donor programs, male fertility, second opinions and location-specific demand. Campaign structure should account for high costs, treatment fit, geography, call handling, landing-page education and the fact that an inquiry may still be months from treatment.
What is GEO for fertility and reproductive health?
GEO, or generative engine optimization, helps AI systems understand the clinic, physicians, services, locations, treatment distinctions, patient populations and trusted sources well enough to answer conversational questions accurately. Clear entities and direct answers matter more than repeating keywords.
How does voice search change fertility marketing?
People ask intimate questions in full sentences, often before they know the clinical term. Pages should answer questions such as who treats recurrent pregnancy loss, where to freeze eggs, what type of doctor evaluates male infertility, how donor eggs work and what to ask an IVF clinic before booking.
Can AI be used in fertility marketing?
Yes, for research, content organization, analytics, repetitive administrative work and search discovery. Sensitive patient data, clinical interpretation, emotional communication, informed consent and consequential care decisions still require appropriate human responsibility and safeguards.
Can you help multi-location fertility groups?
Yes. Multi-location groups need market-by-market demand analysis, physician and service differentiation, local search, scheduling capacity, shared brand standards, referral strategy, call-center performance and enough local specificity that each location feels real rather than copied.
How should a fertility clinic explain treatment costs?
Clear ranges, inclusions, exclusions, medication costs, monitoring, laboratory components, storage, genetic testing, financing and insurance questions can reduce confusion. Exact financial communication depends on the clinic model and payer environment, but hiding the economic structure usually creates more anxiety.
Can you help employer fertility-benefit and navigation companies?
Yes. These companies sell to employers and benefits leaders while also serving members. Marketing has to explain access, network value, navigation, outcomes, member experience, privacy, economics and the difference between the employer buyer and the person receiving care.
What should cryostorage businesses communicate online?
Cryostorage communication should make custody, identification, storage processes, continuity planning, fees, consent and contact procedures understandable. Claims about safety, duration or risk should match actual scientific, operational and legal standards rather than reassurance language invented for marketing.
Can you help reproductive-health nonprofits and advocacy organizations?
Yes. Mission-driven reproductive health organizations may need public education, donor communication, search visibility, policy-neutral service information, community trust, event strategy, storytelling and careful separation between education, advocacy, clinical care and fundraising.
Do you provide medical or legal advice about fertility treatment, surrogacy or reproductive law?
No. I provide marketing, growth, digital, communication and business strategy. Diagnosis, treatment, reproductive law, surrogacy contracts, laboratory compliance, privacy law and other regulated decisions belong with appropriately qualified clinicians, attorneys and compliance professionals.
Do you only work with fertility organizations in Florida?
No. Paper Boat Media is based in DeLand, Florida, but this work can support organizations nationally and internationally when the fit makes sense. Geography matters when laws, insurance, referrals, travel, donor access, competition or patient behavior change by market.
What should a reproductive-health organization measure besides leads?
Useful measures can include consultation quality, show rate, treatment start rate, source mix, referral volume, capacity utilization, cycle economics, patient education engagement, call response, time to appointment, reputation signals, organic and AI discovery, retention where relevant and the quality of handoffs across the care journey.
Where should a fertility or reproductive-health organization start if the problem is unclear?
Start with the business problem. Tell me what is happening with demand, referrals, conversion, reputation, capacity, physician visibility, patient education, geography or growth. I can help determine which marketing, search, website, content, AI or strategic work is most likely to matter.
Can better communication help reduce fertility stigma?
Yes. Clear, nonjudgmental language can make infertility, male-factor fertility, pregnancy loss, donor conception, sexual health and different family-building paths easier to discuss. Good communication should normalize the conversation without trivializing the medical or emotional reality.
How should fertility organizations talk about emotional support after miscarriage or failed treatment?
Support should be visible, specific and easy to access. Organizations can explain counseling referrals, support groups, grief resources, patient coordinators and other available services without pretending that marketing content can replace a qualified mental-health professional. Current ASRM guidance recognizes psychological support as an essential part of miscarriage care.
Tell me what is happening between discovery, trust and treatment.
Maybe physician authority is invisible. Maybe paid search is expensive and poorly matched. Maybe a new location needs demand. Maybe the donor program is hard to explain. Maybe the website feels sterile in the wrong way. Maybe inquiries look strong and treatment starts do not.
Bring me the market, patient journey, service mix, capacity, economics and what feels stuck. I can work outward from there.